USE OF INSULIN SENSITISER, AN INSULIN SECRETAGOGUE AND A BIGUANIDE ANTYHYPERGLYCAEMIC AGENT FOR TREATING DIABETES MELLITIUS

摘要

1. A use of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent as a pharmaceutically acceptable carrier therefor for use as an active therapeutic substance for treating diabetes mellitus and conditions associated with diabetes mellitus, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2.4-dione (Compound I), which comprises the administration of 2 to 12 mg of said Compound. 2. The use according to claim 1, wherein the insulin secretagogue is a repaglinide or a sulphonylurea. 3. The use according to claim 1 or 2, wherein the sulphonylurea is glibenclamide, glipizide, gliclazide, glimepiride, tolazamide or tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibomuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide, glycylamide or repaglinide. 4. The use according to claim 1, wherein the sulphonylurea is selected from glibenclamide from 2,5 to 20 mg, glipizide from 2,5 to 40 mg, gliclazide from 40 to 320 mg, tolazamide from 100 to 1000 mg, tolbutamide from 1000 to 3000 mg, chlorpropamide from 100 to 500 mg and gliquidone from 15 to 180 mg; and a biguanide antihyperglycaemic agent is metformin up to 3000 mg; or a pharmaceutically acceptable derivative each thereof. 5. The use according to claim 1, wherein the biguanide is metformin, buformin or phenformin. 6. The use according to any one of claims 1 to 5, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I). 7. The use according to any one of claims 1 to 6, which comprises the administration of 2 to 4 mg of Compound (I). 8. The use according to any one of claims 1 to 6, which comprises the administration of 4 to 8 mg of Compound (I). 9. The use according to any one of claims 1 to 6, which comprises the administration of 8 to 12 mg of Compound (I). 10. The use according to any one of claims 1 to 6, which comprises the administration of 2 mg of Compound (I). 11. The use according to any one of claims 1 to 6, which comprises the administration of 4 mg of Compound (I). 12. The use according to any one of claims 1 to 6, which comprises the administration of 8 mg of Compound (I). 13. A use of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent as a pharmaceutically acceptable carrier therefor for use as an active therapeutic substance for treating diabetes mellitus and conditions associated with diabetes mellitus, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2.4-dione (Compound I), which comprises the administration of 2 to 12 mg of said Compound, an insulin secretagogue is a sulphonylurea selected from glibenclamide, glipizide, gliclazide, glimepiride, tolazamide or tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibomuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide, glycylamide or repaglinide and the biguanide antihyperglycaemic agent is selected from metformin, buformin or phenformin. 14. A use of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent as a pharmaceutically acceptable carrier therefor for use as an active therapeutic substance for treating diabetes mellitus and conditions associated with diabetes mellitus, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2.4-dione (Compound I) which comprises the administration of 2 to 12 mg of said Compound, the insulin secretagogue is a glimepiride and the a biguanide antihyperglycaemic agent is metformin.